He shorted at $1-looks like he is doing great no? Take this idiots advice and end up working at the same fast food chain where he works wearing a hair net.
You have no idea how I have traded this stock so you do think you know it all- which does not get any more humorous IMO. But keep on protecting the traders and investors from themselves. Last summer it was fenix1357 warning everyone about SPHS and now you! Do yourself a favor and quit posting here because NOBODY listens to you anyway. No disrespect but it's just a reality.
Man you change sides fast! Who does not have any credibility now? How has the story changed besides the miniscule offering? Big game going on here-you will see soon enough IMO. So much fear! So scary! So predictable!
Okay-thanks for the laugh! Enjoy the cult following of 2 guys that own all the insider shares for the company you have fallen in love with! Again "your idea of my motive " exists only in your delusional mind. Good day!
Randall Woods who is currently the CEO did not come to SPHS until August 2012 and the meltdown happened in 2011. I think you need to get some facts straight before you start preaching the word.
Randall E. Woods joined Sophiris as Chief Executive Officer in August 2012 and brings with him 40 years of biotech and pharmaceutical leadership experience. Prior to joining Sophiris, Mr. Woods was President and CEO of Sequel Pharmaceuticals, a spin-out of NovaCardia developing a potential treatment for atrial fibrillation. Mr. Woods was previously the President and CEO of NovaCardia, a pharmaceutical company focused on cardiovascular diseases until its acquisition by Merck & Co for $350 million in 2007. Prior to NovaCardia, Mr. Woods was President and CEO of Corvas International, a publicly held biopharmaceutical company focused on cardiovascular disease and cancer until its acquisition by Dendreon in 2003. Before joining Corvas, he served as President of Boehringer Mannheim’s U.S. Pharmaceutical operations, and spent 20 years at Eli Lilly & Company in various sales and marketing positions. Mr. Woods is a past Chairman for the Advisory Board of UC San Diego’s Sulpizio Family Cardiovascular Center and is a past Chairman of the Board of Directors for BIOCOM, a life science industry association in Southern California. Mr. Woods serves on the Board of Arena Pharmaceuticals and is Chairman of the Board for Sorbent Therapeutics. He received his B.S. in Biology and Chemistry from Ball State University and an MBA in Marketing from Western Michigan University.
I was asking questions about people's conviction with NYMX-nothing more or less. Seems relevent when they are in the same market-no?
My goals with stocks are always to minimize my risk (which I have done with SPHS by selling my original investment) and I trust the management group there-they have a very good track record of selling emerging drugs to bigger pharms.
My discussion was initiated when I noticed the low institutional % of investment in comparison to a direct competitor-DD.
This is for "the in the know" fenix-you are truly good for a laugh and delusional beyond comprehension!
When a person speaks like they are "in the know" like you think you are about how I played SPHS just prove you are envious about others making money when you did NOT. I have seen your recent doubts also NYMX here but nevermind those right?
I entered SPHS at an average of $1.05 at the end of May 2015 and sold about 45% on the pop past $3-at $3.20 to be exact and my current shares are all free. No doubt I had some doubts going into the final P3 results but I never sold a share until after the November news. Keep living in your delusional world-it effects NOBODY but yourself after all!
fenix1357-I have zero motive and could care a less who invests in what. You on the other hand are the same person bashing SPHS and talking people out of potentially making huge returns when the stock was sub .70.. So ask yourself about motives!
I have issues with just trusting 1 or 2 people on investing in an idea. It's great that they are willing to put their own cash at risk but I am also sure that they have cash to burn at this point in their lives. Like I said I wish NYMX investors well and have zero axe to grind between the companies.
I understand but how much difference is there between $1.44 and $2.40 and it was not long ago that NYMX was under $2 and SPHS over $2. Shorts are playing with both of the stocks lately and soon enough the truth will be revealed in PPS. GL with NYMX!
So is SPHS less risky then? I hear it bad mouthed often on this board and they have almost 19% instututional ownership. I know they are basically in the same space or after the same patient market. Very little information when it comes to NYMX from the company in my opinion.
Why do you think there is such low interest from institutions? Just playing devil's advocate here b/c I don't really know much about NYMX except that longs are enamored by Robinson buying many shares.